Business Insights: Global Markets, Strategy & Economic Trends
- Reorient academic medical centers toward integrated translational pipelines connecting patient care, discovery, and commercialization to accelerate therapeutic development.
- Forge sustained industry alliances and new funding models to translate discoveries into scalable products while protecting academic missions.
- Modernize infrastructure, streamline regulatory expertise, and build national talent networks to sustain competitiveness in drug discovery and development.
For more than 50 years, U.S. academic medical centers (AMCs) have been the global engine for pharmaceutical innovation. These university-affiliated hospitals are dedicated to fulfilling the mission areas of medical education, scientific research, and patient care. They have developed a distinctive innovation model in which patient care inspires research questions, public investment supports discovery, and public-private partnerships enable the translation of these breakthroughs into clinical practice. But U.S. AMCs are now facing a major challenge from China, which has emerged as a major rival in the last decade. Its pharmaceuticals R&D sector is on track to become the global industry leader, displacing its U.S. counterpart.
Read the full article from the original source
